Valuation of Medical Innovation Handling with Uncertainty and Risk.

Autor: Nuijten M; A2M, 1546 Lg Amsterdam, The Netherlands.; Department of Biotechnology Engineering, Ben-Gurion University, Beersheba 8410501, Israel., Capri S; School of Economics and Management, Cattaneo-LIUC University, 21053 Castellanza, Italy; scapri@liuc.it.

Publikováno v: Journal of market access & health policy [J Mark Access Health Policy] 2024 Aug 01; Vol. 12 (3), pp. 199-208. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).

An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.

Autor: Desmet T; Healthcare Management Centre, Vlerick Business School, 1210 Brussels, Belgium.; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium., Julian E; Secretariat of the European Access Academy (EAA), 4059 Basel, Switzerland., Van Dyck W; Healthcare Management Centre, Vlerick Business School, 1210 Brussels, Belgium., Huys I; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium., Simoens S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium., Giuliani R; Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK., Toumi M; Public Health Department, Faculty of Medicine, Aix-Marseille University, 13002 Marseille, France., Dierks C; Dierks+ Company, 10115 Berlin, Germany., Dierks J; Dierks+ Company, 10115 Berlin, Germany., Cardone A; Cancer Patients Europe, 1000 Brussels, Belgium., Houÿez F; European Organisation for Rare Diseases (EURORDIS), 75014 Paris, France., Pavlovic M; Medicines Development and Training (MDT) Services, 75020 Paris, France., Berntgen M; European Medicines Agency (EMA), 1083 HS Amsterdam, The Netherlands., Mol P; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands., Schiel A; Norwegian Medicines Agency (NOMA), 0950 Oslo, Norway., Goettsch W; Utrecht Centre for Pharmaceutical Policy, Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, 3584 CS Utrecht, The Netherlands.; National Health Care Institute, 1110 AH Diemen, The Netherlands., Gianfrate F; Department of Economics and Management, University of Ferrara, 44121 Ferrara, Italy., Capri S; School of Economics and Management, Cattaneo-LIUC University, 21053 Castallanza, Italy., Ryan J; Astra Zeneca, Cambridge CB2 8PA, UK., Ducournau P; Abbvie AG, 6330 Cham, Switzerland., Solà-Morales O; HiTT Foundation, International University of Catalonia-UIC, 08015 Barcelona, Spain., Ruof J; Secretariat of the European Access Academy (EAA), 4059 Basel, Switzerland.; Medical School of Hanover, 30625 Hanover, Germany.

Publikováno v: Journal of market access & health policy [J Mark Access Health Policy] 2024 Mar 14; Vol. 12 (1), pp. 21-34. Date of Electronic Publication: 2024 Mar 14 (Print Publication: 2024).

Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles

Autor: Capri, S., Gasparini, R., Panatto, D., Demarteau, N.

Publikováno v: In Gynecologic Oncology 2011 121(3):514-521

The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire .

Autor: Van Haesendonck L; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Ruof J; r-connect Ltd, Basel, Switzerland.; Medical School of Hanover, Hanover, Germany., Desmet T; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Healthcare Management Centre, Vlerick Business School, Brussels, Belgium., Van Dyck W; Healthcare Management Centre, Vlerick Business School, Brussels, Belgium., Simoens S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Huys I; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Giuliani R; Guy's and St Thomas' NHS Foundation Trust, London, UK., Toumi M; Faculty of Medicine, Public Health Department, Aix-Marseille University, Marseille, France., Dierks C; Dierks+Company, Berlin, Germany., Dierks J; Dierks+Company, Berlin, Germany., Cardone A; Cancer Patients Europe Brussels, Belgium., Houÿez F; European Organisation for Rare Diseases (EURORDIS), Paris, France., Pavlovic M; Medicines Development and Training (MDT) Services, Paris, France., Berntgen M; Scientific Evidence Generation department, European Medicines Agency (EMA), Amsterdam, The Netherlands., Mol PGM; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands., Schiel A; Norwegian Medicines Agency (NOMA), Oslo, Norway., Goettsch W; National Health Care Institute, Diemen, The Netherlands., Gianfrate F; University of Ferrara, Ferrara, Italy.; School of Economics and Management, Cattaneo-LIUC University, Castellanza, Italy., Capri S; Health Economics and Payer Evidence, Astra Zeneca, Cambridge, UK., Ryan J; Global Market Access & Pricing, Abbvie AG, Cham, Switzerland., Ducournau P; HiTT Foundation, International University of Catalonia-UIC, Barcelona, Spain., Solà-Morales O; Utrecht Centre for Pharmaceutical Policy, Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, Utrecht, The Netherlands., Julian E; r-connect Ltd, Basel, Switzerland.

Publikováno v: Journal of market access & health policy [J Mark Access Health Policy] 2023 Jun 04; Vol. 11 (1), pp. 2217543. Date of Electronic Publication: 2023 Jun 04 (Print Publication: 2023).

Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs.

Autor: Romandini A; Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy., Baldassarre D; Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.; Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy., Genovese S; Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy., Capri S; School of Economics and Management, Cattaneo-LIUC University, 21053 Castellanza, Varese, Italy., Pompilio G; Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.; Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy., Scatigna M; Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.; Post-Graduate School of Clinical Pharmacology and Toxicology, University of Milan, 20133 Milan, Italy., Werba JP; Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.

Publikováno v: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2023 Jan 24; Vol. 16 (2). Date of Electronic Publication: 2023 Jan 24.